ADMA Biologics (ADMA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Voting matters and shareholder proposals
Election of two Class I directors, Alison C. Finger and Eduardo Rene Salas, for terms expiring at the 2029 annual meeting or until successors are elected and qualified.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Other business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and auditor ratification.
Executive compensation and say-on-pay
Advisory vote scheduled to approve, on a non-binding basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ADMA Biologics
- ASCENIV drove 24% revenue growth, margin expansion, and strong cash flow in Q2 2026.ADMA
Q2 2026 - Directors were elected, all proposals passed, and no shareholder questions were raised.ADMA
AGM 2026 - ASCENIV growth and margin gains offset BIVIGAM declines amid IG market disruption.ADMA
Q1 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with Board support.ADMA
Proxy filing - 2025 revenue up 20% to $510M, with 2026 guidance above $635M and strong margin growth.ADMA
Q4 2025 - Q2 2024 revenue up 78% to $107.2M, net income $32.1M, guidance raised on ASCENIV growth.ADMA
Q2 2024 - Q1 2025 revenue up 40%, margins rise, FDA yield process approved, $500M buyback launched.ADMA
Q1 2025 - New plasma supply deals and yield enhancements position the company for rapid, high-margin growth.ADMA
43rd Annual J.P. Morgan Healthcare Conference 2025 - 2024 revenue up 65% to $426.5M, with record Asceniv demand and raised future guidance.ADMA
Q4 2024